250 related articles for article (PubMed ID: 23982578)
21. Botulinum toxin A injection in the treatment of chronic pelvic pain with hypertonic pelvic floor in women: Treatment techniques and results.
Chuang FC; Yang TH; Kuo HC
Low Urin Tract Symptoms; 2021 Jan; 13(1):5-12. PubMed ID: 32654386
[TBL] [Abstract][Full Text] [Related]
22. Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence.
Chen CL; Meng E
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32050685
[TBL] [Abstract][Full Text] [Related]
23. Localized myofascial pain responds better than referring myofascial pain to botulinum toxin injections.
Abboud WA; Hassin-Baer S; Joachim M; Givol N; Yahalom R
Int J Oral Maxillofac Surg; 2017 Nov; 46(11):1417-1423. PubMed ID: 28521968
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of PrabotulinumtoxinA (Nabota
Kim DY; Kim JM
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30177597
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin for myofascial pain syndromes in adults.
Soares A; Andriolo RB; Atallah AN; da Silva EM
Cochrane Database Syst Rev; 2012 Apr; (4):CD007533. PubMed ID: 22513950
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series.
Baker JS; Nolan PJ
J Am Dent Assoc; 2017 Jan; 148(1):33-39. PubMed ID: 28314397
[TBL] [Abstract][Full Text] [Related]
27. Botulinum toxin infiltrations versus local anaesthetic infiltrations in pelvic floor myofascial pain: Multicentre, randomized, double-blind study.
Levesque A; Ploteau S; Michel F; Siproudhis L; Bautrant E; Eggermont J; Rabischong B; Volteau C; Perrouin-Verbe MA; Labat JJ
Ann Phys Rehabil Med; 2021 Jan; 64(1):101354. PubMed ID: 31981833
[TBL] [Abstract][Full Text] [Related]
28. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders.
Karp BI; Tandon H; Vigil D; Stratton P
Int Urogynecol J; 2019 Jul; 30(7):1071-1081. PubMed ID: 30617506
[TBL] [Abstract][Full Text] [Related]
29. Is Botox for anal pain an effective treatment option?
Bibi S; Zutshi M; Gurland B; Hull T
Postgrad Med; 2016 Jan; 128(1):41-5. PubMed ID: 26308909
[TBL] [Abstract][Full Text] [Related]
30. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
[TBL] [Abstract][Full Text] [Related]
31. Anal sphincter botulinum toxin injection in children with functional anorectal and colonic disorders: A large institutional study and review of the literature focusing on complications.
Halleran DR; Lu PL; Ahmad H; Paradiso MM; Lehmkuhl H; Akers A; Hallagan A; Bali N; Vaz K; Yacob D; Di Lorenzo C; Levitt MA; Wood RJ
J Pediatr Surg; 2019 Nov; 54(11):2305-2310. PubMed ID: 31060739
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review.
Ho KY; Tan KH
Eur J Pain; 2007 Jul; 11(5):519-27. PubMed ID: 17071119
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin type A and myofascial pain syndrome: a retrospective study of 301 patients.
Avendaño-Coy J; Gómez-Soriano J; Valencia M; Estrada J; Leal F; Ruiz-Campa R
J Back Musculoskelet Rehabil; 2014; 27(4):485-92. PubMed ID: 24867895
[TBL] [Abstract][Full Text] [Related]
34. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans.
De Andrés J; Adsuara VM; Palmisani S; Villanueva V; López-Alarcón MD
Reg Anesth Pain Med; 2010; 35(3):255-60. PubMed ID: 20921836
[TBL] [Abstract][Full Text] [Related]
35. Botox® after Botox® - a new approach to treat diplopia secondary to cosmetic botulinic toxin use: case reports.
Isaac CR; Chalita MR; Pinto LD
Arq Bras Oftalmol; 2012; 75(3):213-4. PubMed ID: 22872208
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the Efficacy of Botulinum Toxin, Local Anesthesia, and Platelet-Rich Plasma Injections in Patients With Myofascial Trigger Points in the Masseter Muscle.
Yilmaz O; Sivrikaya EC; Taskesen F; Pirpir C; Ciftci S
J Oral Maxillofac Surg; 2021 Jan; 79(1):88.e1-88.e9. PubMed ID: 33045182
[TBL] [Abstract][Full Text] [Related]
37. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
[TBL] [Abstract][Full Text] [Related]
38. The use of botulinum toxins for the management of chronic pain and headache: making the most of an evidence-based medicine approach for these rapidly evolving treatments.
Argoff CE
Pain Med; 2011 Nov; 12(11):1581-2. PubMed ID: 22082137
[No Abstract] [Full Text] [Related]
39. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?
Benecke R; Heinze A; Reichel G; Hefter H; Göbel H;
Pain Med; 2011 Nov; 12(11):1607-14. PubMed ID: 21692970
[TBL] [Abstract][Full Text] [Related]
40. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Silberstein S; Mathew N; Saper J; Jenkins S
Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
